



## Complete Summary

---

### TITLE

Diagnosis and management of chronic obstructive pulmonary disease (COPD): percentage of patients with COPD whose physician inquired about smoking cessation (if patient a smoker) at every visit.

### SOURCE(S)

Institute for Clinical Systems Improvement (ICSI). Diagnosis and management of chronic obstructive pulmonary disease (COPD). Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2009 Jan. 51 p. [97 references]

## Measure Domain

### PRIMARY MEASURE DOMAIN

Process

The validity of measures depends on how they are built. By examining the key building blocks of a measure, you can assess its validity for your purpose. For more information, visit the [Measure Validity](#) page.

### SECONDARY MEASURE DOMAIN

Does not apply to this measure

## Brief Abstract

### DESCRIPTION

This measure is used to assess the percentage of patients with chronic obstructive pulmonary disease (COPD) who are asked about smoking cessation (if patient a smoker) at every visit.

### RATIONALE

The priority aim addressed by this measure is to increase the number of patients with chronic obstructive pulmonary disease (COPD) who receive information on the options for tobacco cessation and information on the risks of continued smoking.

### PRIMARY CLINICAL COMPONENT

Chronic obstructive pulmonary disease (COPD); smoking cessation

**DENOMINATOR DESCRIPTION**

Patients with a diagnosis of chronic obstructive pulmonary disease (COPD) who have an indication in their charts that they are users of tobacco who present for a clinic visit within the reporting month

**NUMERATOR DESCRIPTION**

Number of patients with documentation in the chart that the patient was asked about a change in smoking status and/or readiness to quit

**Evidence Supporting the Measure**

**EVIDENCE SUPPORTING THE CRITERION OF QUALITY**

- A clinical practice guideline or other peer-reviewed synthesis of the clinical evidence

**Evidence Supporting Need for the Measure**

**NEED FOR THE MEASURE**

Unspecified

**State of Use of the Measure**

**STATE OF USE**

Current routine use

**CURRENT USE**

Internal quality improvement

**Application of Measure in its Current Use**

**CARE SETTING**

Physician Group Practices/Clinics

**PROFESSIONALS RESPONSIBLE FOR HEALTH CARE**

Physicians

**LOWEST LEVEL OF HEALTH CARE DELIVERY ADDRESSED**

Group Clinical Practices

**TARGET POPULATION AGE**

Unspecified

**TARGET POPULATION GENDER**

Either male or female

**STRATIFICATION BY VULNERABLE POPULATIONS**

Unspecified

**Characteristics of the Primary Clinical Component**

**INCIDENCE/PREVALENCE**

Unspecified

**ASSOCIATION WITH VULNERABLE POPULATIONS**

Historically viewed as a man's disease, more women have died of chronic obstructive pulmonary disease (COPD) than men each year since 2000.

**EVIDENCE FOR ASSOCIATION WITH VULNERABLE POPULATIONS**

Institute for Clinical Systems Improvement (ICSI). Diagnosis and management of chronic obstructive pulmonary disease (COPD). Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2009 Jan. 51 p. [97 references]

**BURDEN OF ILLNESS**

Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States and is the only common chronic illness for which mortality rates continue to increase.

**EVIDENCE FOR BURDEN OF ILLNESS**

Institute for Clinical Systems Improvement (ICSI). Diagnosis and management of chronic obstructive pulmonary disease (COPD). Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2009 Jan. 51 p. [97 references]

**UTILIZATION**

Unspecified

**COSTS**

Unspecified

## Institute of Medicine National Healthcare Quality Report Categories

### IOM CARE NEED

Getting Better  
Living with Illness

### IOM DOMAIN

Effectiveness

## Data Collection for the Measure

### CASE FINDING

Users of care only

### DESCRIPTION OF CASE FINDING

Patients with chronic obstructive pulmonary disease (COPD) who have any indication on their charts that they are users of tobacco who presented to the clinic within a designated time period

Identify patients with a clinic visit in the reporting month who meet the inclusion criteria. Data may be collected by medical record review.

Randomly selected cases may be reviewed monthly.

### DENOMINATOR SAMPLING FRAME

Patients associated with provider

### DENOMINATOR INCLUSIONS/EXCLUSIONS

#### Inclusions

Patients with a diagnosis of chronic obstructive pulmonary disease (COPD) who have an indication in their charts that they are users of tobacco who present for a clinic visit within the reporting month

#### Exclusions

Unspecified

### RELATIONSHIP OF DENOMINATOR TO NUMERATOR

All cases in the denominator are equally eligible to appear in the numerator

### DENOMINATOR (INDEX) EVENT

Clinical Condition  
Encounter  
Patient Characteristic

#### **DENOMINATOR TIME WINDOW**

Time window is a single point in time

#### **NUMERATOR INCLUSIONS/EXCLUSIONS**

##### **Inclusions**

Number of patients with documentation in the chart that the patient was asked about a change in smoking status and/or readiness to quit

##### **Exclusions**

Unspecified

#### **MEASURE RESULTS UNDER CONTROL OF HEALTH CARE PROFESSIONALS, ORGANIZATIONS AND/OR POLICYMAKERS**

The measure results are somewhat or substantially under the control of the health care professionals, organizations and/or policymakers to whom the measure applies.

#### **NUMERATOR TIME WINDOW**

Encounter or point in time

#### **DATA SOURCE**

Medical record

#### **LEVEL OF DETERMINATION OF QUALITY**

Individual Case

#### **PRE-EXISTING INSTRUMENT USED**

Unspecified

### **Computation of the Measure**

#### **SCORING**

Rate

#### **INTERPRETATION OF SCORE**

Better quality is associated with a higher score

## ALLOWANCE FOR PATIENT FACTORS

Unspecified

## STANDARD OF COMPARISON

Internal time comparison

## Evaluation of Measure Properties

## EXTENT OF MEASURE TESTING

Unspecified

## Identifying Information

## ORIGINAL TITLE

Percentage of patients with COPD who are asked about smoking cessation (if patient a smoker) at every visit.

## MEASURE COLLECTION

[Diagnosis and Management of Chronic Obstructive Pulmonary Disease \(COPD\) Measures](#)

## DEVELOPER

Institute for Clinical Systems Improvement

## FUNDING SOURCE(S)

The following Minnesota health plans provide direct financial support: Blue Cross and Blue Shield of Minnesota, HealthPartners, Medica, Metropolitan Health Plan, PreferredOne and UCare Minnesota. In-kind support is provided by the Institute for Clinical Systems Improvement's (ICSI) members.

## COMPOSITION OF THE GROUP THAT DEVELOPED THE MEASURE

*Work Group Members:* Charlene McEvoy, MD, MPH (Work Group Leader) (HealthPartners Regions Hospital); Allen Horn, MD (CentraCare Clinic) (Family Medicine); G. Paul Kerestes, MD (Allina Medical Clinic) (Family Medicine); Rhonda Schneider, RN, MSN (Marshfield Clinic) (Nursing and Health Education); Catherine Youngman, RN (HealthPartners Medical Group) (Nursing and Health Education); Anne Schullo-Feulner, PharmD (Park Nicollet Health Services) (Pharmacy); Blair Anderson, MD (HealthPartners Medical Group) (Pulmonary & Critical Care Medicine); Scott Copeman, RRT, RCP (Mayo Clinic) (Respiratory Therapy); Jeff Norton, CRT, RCP (Fairview Health Services) (Respiratory Therapy); Teresa Huntman, RRT, CPHQ (Institute for Clinical Systems Improvement) (Facilitator);

Linda Setterlund, MA, CPHQ (Institute for Clinical Systems Improvement)  
(Facilitator)

## **FINANCIAL DISCLOSURES/OTHER POTENTIAL CONFLICTS OF INTEREST**

ICSI has adopted a policy of transparency, disclosing potential conflict and competing interests of all individuals who participate in the development, revision and approval of ICSI documents (guidelines, order sets and protocols). This applies to all work groups (guidelines, order sets and protocols) and committees (Committee on Evidence-Based Practice, Cardiovascular Steering Committee, Women's Health Steering Committee, Preventive & Health Maintenance Steering Committee and Respiratory Steering Committee).

Participants must disclose any potential conflict and competing interests they or their dependents (spouse, dependent children, or others claimed as dependents) may have with any organization with commercial, proprietary, or political interests relevant to the topics covered by ICSI documents. Such disclosures will be shared with all individuals who prepare, review and approve ICSI documents.

Charlene McEvoy, MD, has been a part of a Speaker's Bureau and participated in Research/Grant Funding for Pfizer and Spiration, Inc. All funds go to HealthPartners Research Foundation.

Barbara Yawn, MD, has received honorariums and participated in Research/Grant Funding for BJ/Pfizer, GSK and AZ. All funds paid to Olmsted Medical Center. No funds received personally.

No other work group members have potential conflicts of interest to disclose.

## **ADAPTATION**

Measure was not adapted from another source.

## **RELEASE DATE**

2003 Dec

## **REVISION DATE**

2009 Jan

## **MEASURE STATUS**

This is the current release of the measure.

This measure updates a previous version: Institute for Clinical Systems Improvement (ICSI). Chronic obstructive pulmonary disease. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2007 Jan. 65 p.

## **SOURCE(S)**

Institute for Clinical Systems Improvement (ICSI). Diagnosis and management of chronic obstructive pulmonary disease (COPD). Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2009 Jan. 51 p. [97 references]

## **MEASURE AVAILABILITY**

The individual measure, "Percentage of Patients with COPD Who Are Asked About Smoking Cessation (If Patient a Smoker) at Every Visit," is published in "Health Care Guideline: Diagnosis and Management of Chronic Obstructive Pulmonary Disease." This document is available from the [Institute for Clinical Systems Improvement \(ICSI\) Web site](http://www.icsi.org).

For more information, contact ICSI at, 8009 34th Avenue South, Suite 1200, Bloomington, MN 55425; phone: 952-814-7060; fax: 952-858-9675; Web site: [www.icsi.org](http://www.icsi.org); e-mail: [icsi.info@icsi.org](mailto:icsi.info@icsi.org)

## **NQMC STATUS**

This NQMC summary was completed by ECRI on July 14, 2004. The summary was updated by ECRI Institute on February 25, 2005, January 25, 2006, April 4, 2007, and again on June 22, 2009.

## **COPYRIGHT STATEMENT**

This NQMC summary (abstracted Institute for Clinical Systems Improvement [ICSI] Measure) is based on the original measure, which is subject to the measure developer's copyright restrictions.

The abstracted ICSI Measures contained in this Web site may be downloaded by any individual or organization. If the abstracted ICSI Measures are downloaded by an individual, the individual may not distribute copies to third parties.

If the abstracted ICSI Measures are downloaded by an organization, copies may be distributed to the organization's employees but may not be distributed outside of the organization without the prior written consent of the Institute for Clinical Systems Improvement, Inc.

All other copyright rights in the abstracted ICSI Measures are reserved by the Institute for Clinical Systems Improvement, Inc. The Institute for Clinical Systems Improvement, Inc. assumes no liability for any adaptations or revisions or modifications made to the abstracts of the ICSI Measures.

## **Disclaimer**

### **NQMC DISCLAIMER**

The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.



All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria which may be found at <http://www.qualitymeasures.ahrq.gov/about/inclusion.aspx>.

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. The inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.

[Copyright/Permission Requests](#)

Date Modified: 9/14/2009

